公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial | Reich K.; Gooderham M.; Tha?i D.; Crowley J.J.; Ryan C.; Krueger J.G.; TSEN-FANG TSAI ; Flack M.; Gu Y.; Williams D.A.; Thompson E.H.Z.; Paul C. | The Lancet | 191 | 157 | |
2020 | Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials | Puig L.; TSEN-FANG TSAI ; Bhutani T.; Uy J.; Ramachandran P.; Song M.; You Y.; Gooderham M.; Lebwohl M. | Journal of the European Academy of Dermatology and Venereology | 23 | 17 |